Natalizumab treatment leads to an increase in circulating CXCR3-expressing B cells

Abstract

The rapid and persistent increase in circulating CXCR3-expressing B cells in response to natalizumab treatment possibly reflects the relevance of this chemokine receptor in controlling migration of B cells into the CNS in humans in vivo.